… by a tumor suppressor gene, frequently lost in lung cancer, RBM5 (RNA-binding motif protein
5; … correlate positively with lymph node metastasis in lung cancer patients [47]. Two other …

… of local and distant failure in resected lung cancer: implications for reported rates of local …
recurrence and second primary lung cancer in early-stage lung cancer survivors followed with …

… lung cancer, whereas PFS is only moderately associated with OS. Therefore, subsequent
treatment after disease progression … that even in advanced lung cancer, PPS, rather than PFS, …

… In 2018, lung cancer was responsible for approximately 1.8 million deaths globally, with 2.1
… subtypes of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer. …

… PRO measures used in routine care provide clinicians with relevant prognostic information
about patients with lung cancer at disease progression. These results show the potential …

… for p-Stage I lung cancer patients is good as compared with the literature. Whereas the
reported 5-year survival for p-Stage I patients with non-small cell lung cancer is about 60% [1], it …

… We found that clinical progression of disease occurred in 13% of patients at only 4 weeks.
Clinical progression rates at 8 and 16 weeks were 31% and 46%, respectively. The likelihood …

… morphologic progression seen in archived sputum cells as the paradigm of neoplastic
development in the lung. Although the NCI collaborative trials had shown that this progression is …

… Patients and Methods We identified 19 patients with lung cancer who had staging PET-CT
scans before any therapy, and adequate follow-up (complete to time of progression for 18, …

… important in predicting the clinical course of lung cancerpatients. In this study, … lung cancer
patients to determine whetherthis parameter might be used to evaluate disease progression. …